Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1201txs

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS	4	APR 04	STN AnaVist $500 visualization usage credit offered
NEWS	5	MAY 10	CA/CAplus enhanced with 1900-1906 U.S. patent records
NEWS	6	MAY 11	KOREAPAT updates resume
NEWS	7	MAY 19	Derwent World Patents Index to be reloaded and enhanced
NEWS	8	MAY 30	IPC 8 Rolled-up Core codes added to CA/CAplus and USPATFULL/USPAT2
NEWS	9	MAY 30	The F-Term thesaurus is now available in CA/CAplus
NEWS	10	JUN 02	The first reclassification of IPC codes now complete in INPADOC
NEWS	11	JUN 26	TULSA/TULSA2 reloaded and enhanced with new search and and display fields
NEWS	12	JUN 28	Price changes in full-text patent databases EPFULL and PCTFULL
NEWS	13	JUl 11	CHEMSAFE reloaded and enhanced
NEWS	14	JUl 14	FSTA enhanced with Japanese patents
NEWS	15	JUl 19	Coverage of Research Disclosure reinstated in DWPI
NEWS	16	AUG 09	INSPEC enhanced with 1898-1968 archive

NEWS EXPRESS JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8
NEWS X25	X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:47:37 ON 09 AUG 2006

=> file reg
COST IN U.S. DOLLARS SINCE FILE TOTAL

	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 14:47:52 ON 09 AUG 2006

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 8 AUG 2006 HIGHEST RN 899769-93-8
DICTIONARY FILE UPDATES: 8 AUG 2006 HIGHEST RN 899769-93-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10728339.str



chain nodes :
6 12 13 14
ring nodes :
1 2 3 4 5 7 8 9 10 11
chain bonds :
1-6 5-12 6-11 12-13 12-14
ring bonds :
1-2 1-5 2-3 3-4 4-5 7-8 7-11 8-9 9-10 10-11
exact/norm bonds :
1-2 1-5 1-6 2-3 3-4 10-11 12-13 12-14
exact bonds :
4-5 5-12 6-11 7-8 7-11 8-9 9-10
isolated ring systems :
containing 1 : 7 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:CLASS 13:CLASS 14:CLASS

L1 STRUCTURE UPLOADED

=> s l1
SAMPLE SEARCH INITIATED 14:48:11 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 3 TO ITERATE

100.0% PROCESSED 3 ITERATIONS 1 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 3 TO 163
PROJECTED ANSWERS: 1 TO 80

L2 1 SEA SSS SAM L1

=> s l1 ful
FULL SEARCH INITIATED 14:48:20 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 74 TO ITERATE

100.0% PROCESSED 74 ITERATIONS 23 ANSWERS
SEARCH TIME: 00.00.01

L3 23 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	166.94	167.15

FILE 'CAPLUS' ENTERED AT 14:48:33 ON 09 AUG 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907 - 9 Aug 2006 VOL 145 ISS 7
FILE LAST UPDATED: 8 Aug 2006 (20060808/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

```
=> s l3
L4            2 L3

=> d l4 ibib hitstr abs 1-2

L4   ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:         2004:1011962  CAPLUS
DOCUMENT NUMBER:          142:6532
TITLE:                    Preparation of imidazolecarboxamides as factor Xa
                          and/or factor VIIa inhibitors
INVENTOR(S):              Nazare, Marc; Bauer, Armin; Wehner, Volkmar; Will,
                          David William; Matter, Hans; Wagner, Michael;
                          Schreuder, Herman
PATENT ASSIGNEE(S):       Aventis Pharma Deutschland GmbH, Germany
SOURCE:                   Eur. Pat. Appl., 90 pp.
                          CODEN: EPXXDW
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   2
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
     EP 1479674            A1    20041124    EP 2003-11307           20030519
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
     CA 2507624            AA    20040617    CA 2003-2507624         20031120
     WO 2004050636         A2    20040617    WO 2003-EP12996         20031120
     WO 2004050636         A3    20041014
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
             PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,
             TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
             BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
             ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
             TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     AU 2003285336         A1    20040623    AU 2003-285336          20031120
     EP 1569927            A2    20050907    EP 2003-778324          20031120
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
     BR 2003017003         A     20051025    BR 2003-17003           20031120
     JP 2006514093         T2    20060427    JP 2004-570676          20031120
     US 2004171604         A1    20040902    US 2003-728339          20031204
PRIORITY APPLN. INFO.:                       EP 2002-27120       A   20021204
                                             US 2003-463449P     P   20030416
                                             EP 2003-11307       A   20030519
                                             US 2003-507338P     P   20030930
                                             WO 2003-EP12996     W   20031120

OTHER SOURCE(S):          MARPAT 142:6532
IT   701292-53-7P 701292-61-7P 701292-62-8P
     701292-65-1P 701292-69-5P 701292-75-3P
     701292-76-4P 701292-77-5P 701292-78-6P
     701292-79-7P 701292-80-0P 701292-81-1P
     701292-82-2P 701292-86-6P 701292-87-7P
     701292-92-4P 701292-99-1P 701293-13-2P
     701293-14-3P 796857-04-0P 796857-06-2P
```

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(claimed compound; preparation of imidazolecarboxamides as factor Xa and/or factor VIIa inhibitors)

RN 701292-53-7 CAPLUS
CN 1H-Imidazole-5-carboxamide, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-N-[1-(1-methylethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 701292-61-7 CAPLUS
CN 1H-Imidazole-5-carboxamide, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-4-methyl-N-[1-(1-methylethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 701292-62-8 CAPLUS
CN 1H-Imidazole-5-carboxamide, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-2-ethyl-4-methyl-N-[1-(1-methylethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 701292-65-1 CAPLUS
CN 1H-Imidazole-5-carboxamide, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-2-iodo-4-methyl-N-[1-(1-methylethyl)-4-piperidinyl]-(9CI) (CA INDEX NAME)



RN 701292-69-5 CAPLUS
CN 1H-Imidazole-5-carboxamide, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-2-(methoxymethyl)-N-[1-(1-methylethyl)-4-piperidinyl]-(9CI) (CA INDEX NAME)



RN 701292-75-3 CAPLUS
CN 1H-Imidazole-5-carboxamide, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-2-cyclopropyl-N-[1-(1-methylethyl)-4-piperidinyl]-(9CI) (CA INDEX NAME)



RN 701292-76-4 CAPLUS
CN 1H-Imidazole-5-carboxamide, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-2-(2,6-difluorophenyl)-N-[1-(1-methylethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 701292-77-5 CAPLUS
CN 1H-Imidazole-5-carboxamide, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-2-cyclopentyl-N-[1-(1-methylethyl)-4-piperidinyl]-(9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 701292-78-6 CAPLUS
CN 1H-Imidazole-5-carboxamide, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-2-(2-methoxyethyl)-N-[1-(1-methylethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 701292-79-7 CAPLUS
CN 1H-Imidazole-5-carboxamide, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-2-(2,6-dichlorophenyl)-N-[1-(1-methylethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 701292-80-0 CAPLUS
CN 1H-Imidazole-5-carboxamide, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-2-(1-methylethyl)-N-[1-(1-methylethyl)-4-piperidinyl]-(9CI) (CA INDEX NAME)



RN 701292-81-1 CAPLUS
CN 1H-Imidazole-5-carboxamide, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-N-[1-(1-methylethyl)-4-piperidinyl]-2-(2-pyridinyl)-(9CI) (CA INDEX NAME)



RN 701292-82-2 CAPLUS
CN 1H-Imidazole-5-carboxamide, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-4-methyl-N-[1-(1-methylethyl)-4-piperidinyl]-2-phenyl-(9CI) (CA INDEX NAME)



RN 701292-86-6 CAPLUS
CN 1H-Imidazole-5-carboxamide, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-N-[1-(1-methylethyl)-4-piperidinyl]-2-(3-pyridinyl)-(9CI) (CA INDEX NAME)



RN 701292-87-7 CAPLUS
CN 1H-Imidazole-5-carboxamide, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-N-[1-(1-methylethyl)-4-piperidinyl]-2-(2-methyl-4-thiazolyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 701292-92-4 CAPLUS
CN 1H-Imidazole-5-carboxamide, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-2-(ethylsulfonyl)-N-[1-(1-methylethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 701292-99-1 CAPLUS
CN 1H-Imidazole-5-carboxamide, 2-bromo-1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-4-methyl-N-[1-(1-methylethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 701293-13-2 CAPLUS
CN 1H-Imidazole-5-carboxamide, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-2-(2-methoxyphenyl)-4-methyl-N-[1-(1-methylethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 701293-14-3 CAPLUS
CN 1H-Imidazole-5-carboxamide, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-N-[1-(1-methylethyl)-4-piperidinyl]-2-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 796857-04-0 CAPLUS
CN 1H-Imidazole-2,5-dicarboxamide, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-4-methyl-N5-[1-(1-methylethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 796857-06-2 CAPLUS
CN 1H-Imidazole-2-carboxylic acid, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-5-[[[1-(1-methylethyl)-4-piperidinyl]amino]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)



IT 701292-59-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of imidazolecarboxamides as factor Xa and/or factor VIIa inhibitors)
RN 701292-59-3 CAPLUS
CN 1H-Imidazole-5-carboxamide, 4-chloro-1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-N-[1-(1-methylethyl)-4-piperidinyl]-2-phenyl- (9CI) (CA INDEX NAME)



IT 796857-12-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of imidazolecarboxamides as factor Xa and/or factor VIIa inhibitors)
RN 796857-12-0 CAPLUS
CN 1H-Imidazole-5-carboxamide, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-2-iodo-4-methyl-N-[1-(1-methylethyl)-4-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 701292-65-1
CMF C21 H25 Cl I N5 O2 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2



GI



I

AB Title compds. [I; R = (substituted) mono- or bicyclic aryl, pyridinyl, pyrimidinyl, indolyl, isoindolyl, indazolyl, phthalazinyl, quinolyl, etc.; Q = bond, aminocarbonylalkyl, aminocarbonylamino, carbonylamino, etc.; R1 = H, (substituted) alkyl, aryl, heterocyclyl, etc.; R2 = bond, alkylene; R1R3 = atoms to form a (substituted) 6-8 membered ring containing 1-4 N, O, S atoms; R1NR2V = atoms to form a (substituted) 4-8 membered ring containing 1-4 N, O, S atoms; R3, R4 = H, halo, NO2, cyano, hydroxyaminocarbonyl, methoxyaminocarbonyl, (substituted) alkyl, Ph, aminoalkyl, sulfonylamino, heterocyclylalkyl, cycloalkylalkyl, specified azolyl, etc.; G = bond,

(CH2)mNR10SO2NR10(CH2)n, etc.; m, n = 0-6; M = H, (substituted) alkyl, aminocarbonyl, aminoalkyl, etc.; R10 = H, alkyl, hydroxyalkyl, alkoxyalkyl, perfluoroalkyl], were prepared Thus, 3-[5-(5-chlorothiophen-2-yl)isoxazol-3-ylmethyl]-2-iodo-5-methyl-3H-imidazole-4-carboxylic acid (preparation given), N-ethylmorpholine, and TOTU were stirred 30 min. in CH2Cl2; 1-isopropylpiperidin-4-ylamine hydrochloride (preparation given) was added followed by stirring for 2 h to give thus, 3-[5-(5-chlorothiophen-2-yl)isoxazol-3-ylmethyl]-2-iodo-5-methyl-3H-imidazole-4-carboxylic acid (1-isopropylpiperidin-4-yl)amide, isolated as the trifluoroacetate. The latter inhibited factor Xa with Ki = 0.001 μM.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:470325 CAPLUS
DOCUMENT NUMBER: 141:38613
TITLE: A preparation of imidazole derivatives, useful as factor Xa inhibitors
PATENT ASSIGNEE(S): Aventis Pharma Deutschland G.m.b.H., Germany
SOURCE: Eur. Pat. Appl., 66 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
EP 1426364	A1	20040609	EP 2002-27120		20021204
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK					
CA 2507624	AA	20040617	CA 2003-2507624		20031120
WO 2004050636	A2	20040617	WO 2003-EP12996		20031120
WO 2004050636	A3	20041014			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
AU 2003285336	A1	20040623	AU 2003-285336		20031120
EP 1569927	A2	20050907	EP 2003-778324		20031120
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
BR 2003017003	A	20051025	BR 2003-17003		20031120
JP 2006514093	T2	20060427	JP 2004-570676		20031120
US 2004171604	A1	20040902	US 2003-728339		20031204
PRIORITY APPLN. INFO.:			EP 2002-27120	A	20021204
			US 2003-463449P	P	20030416
			EP 2003-11307	A	20030519
			US 2003-507338P	P	20030930
			WO 2003-EP12996	W	20031120

OTHER SOURCE(S): MARPAT 141:38613
IT 701292-53-7P 701292-59-3P 701292-61-7P
701292-62-8P 701292-65-1P 701292-69-5P
701292-75-3P 701292-76-4P 701292-77-5P

701292-78-6P 701292-79-7P 701292-80-0P
701292-81-1P 701292-82-2P 701292-86-6P
701292-87-7P 701292-92-4P 701292-99-1P
701293-13-2P 701293-14-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of imidazole derivs. useful as factor Xa inhibitors)

RN 701292-53-7 CAPLUS
CN 1H-Imidazole-5-carboxamide, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-N-[1-(1-methylethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 701292-59-3 CAPLUS
CN 1H-Imidazole-5-carboxamide, 4-chloro-1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-N-[1-(1-methylethyl)-4-piperidinyl]-2-phenyl- (9CI) (CA INDEX NAME)



RN 701292-61-7 CAPLUS
CN 1H-Imidazole-5-carboxamide, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-4-methyl-N-[1-(1-methylethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 701292-62-8 CAPLUS
CN 1H-Imidazole-5-carboxamide, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-2-ethyl-4-methyl-N-[1-(1-methylethyl)-4-piperidinyl]-(9CI) (CA INDEX NAME)



RN 701292-65-1 CAPLUS
CN 1H-Imidazole-5-carboxamide, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-2-iodo-4-methyl-N-[1-(1-methylethyl)-4-piperidinyl]-(9CI) (CA INDEX NAME)



RN 701292-69-5 CAPLUS
CN 1H-Imidazole-5-carboxamide, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-2-(methoxymethyl)-N-[1-(1-methylethyl)-4-piperidinyl]-(9CI) (CA INDEX NAME)



RN 701292-75-3 CAPLUS
CN 1H-Imidazole-5-carboxamide, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-2-cyclopropyl-N-[1-(1-methylethyl)-4-piperidinyl]-(9CI) (CA INDEX NAME)



RN 701292-76-4 CAPLUS
CN 1H-Imidazole-5-carboxamide, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-2-(2,6-difluorophenyl)-N-[1-(1-methylethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 701292-77-5 CAPLUS
CN 1H-Imidazole-5-carboxamide, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-2-cyclopentyl-N-[1-(1-methylethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 701292-78-6 CAPLUS
CN 1H-Imidazole-5-carboxamide, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-2-(2-methoxyethyl)-N-[1-(1-methylethyl)-4-piperidinyl]-(9CI) (CA INDEX NAME)



RN 701292-79-7 CAPLUS
CN 1H-Imidazole-5-carboxamide, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-2-(2,6-dichlorophenyl)-N-[1-(1-methylethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 701292-80-0 CAPLUS
CN 1H-Imidazole-5-carboxamide, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-2-(1-methylethyl)-N-[1-(1-methylethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 701292-81-1 CAPLUS
CN 1H-Imidazole-5-carboxamide, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-N-[1-(1-methylethyl)-4-piperidinyl]-2-(2-pyridinyl)-(9CI) (CA INDEX NAME)



RN 701292-82-2 CAPLUS
CN 1H-Imidazole-5-carboxamide, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-4-methyl-N-[1-(1-methylethyl)-4-piperidinyl]-2-phenyl-(9CI) (CA INDEX NAME)



RN 701292-86-6 CAPLUS
CN 1H-Imidazole-5-carboxamide, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-N-[1-(1-methylethyl)-4-piperidinyl]-2-(3-pyridinyl)-(9CI) (CA INDEX NAME)



RN 701292-87-7 CAPLUS
CN 1H-Imidazole-5-carboxamide, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-N-[1-(1-methylethyl)-4-piperidinyl]-2-(2-methyl-4-thiazolyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 701292-92-4 CAPLUS
CN 1H-Imidazole-5-carboxamide, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-2-(ethylsulfonyl)-N-[1-(1-methylethyl)-4-piperidinyl]-(9CI) (CA INDEX NAME)



RN 701292-99-1 CAPLUS
CN 1H-Imidazole-5-carboxamide, 2-bromo-1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-4-methyl-N-[1-(1-methylethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 701293-13-2 CAPLUS
CN 1H-Imidazole-5-carboxamide, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-2-(2-methoxyphenyl)-4-methyl-N-[1-(1-methylethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 701293-14-3 CAPLUS
CN 1H-Imidazole-5-carboxamide, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-N-[1-(1-methylethyl)-4-piperidinyl]-2-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to a preparation of imidazole derivs. of formula I [wherein: R1 is H, (un)substituted alkyl, monocyclic or bicyclic aryl, etc.; R2 is a bond or alkylene; R1 and R3 together with the atoms to which they are bonded from a 4-7-membered ring containing 1-4 heteroatoms; R1-N-R2-V form a 4-7-membered ring containing 1-4 heteroatoms; or R3 and R4 are independently selected from H, halogen, alkyl, Ph, NO2, CN, or OH, etc.; R5 is monocyclic or bicyclic (hetero)aryl; Q is a bond, alkylene, SO2, or NHC(O)NH, etc.; M is H, (hetero)aryl, cycloalkyl, C(O)NH2, etc.; V is (hetero)aryl or a cyclic residue; G is a bond or -(CH2)1-6-NH-SO2-NH-

(CH2)1-6, etc.], useful as factor Xa inhibitors. The invented compds. exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenosis. Compds. I are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can be applied in conditions in which an undesired activity of factor Xa and/or factor VIIa is present, or for the cure or prevention of which an inhibition of factor Xa and/or factor VIIa is intended. For instance, imidazole derivative II (inhibition constant of factor Xa is 0.065 μM) was prepared via N-alkylation of Me 3H-imidazole-4-carboxylate by isoxazole derivative III, hydrolysis of the obtained imidazolecarboxylate derivative IV, and subsequent amidation by (1-isopropyl-piperidine-4-yl)amine hydrochloride (example 1).

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	10.68	177.83

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-1.50	-1.50

STN INTERNATIONAL LOGOFF AT 14:49:06 ON 09 AUG 2006